Q-omics provides the consensus-scored PTCH1 profile across patient tissues and cancer cell-line models. PTCH1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PTCH1 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PTCH1 RNA expression shows 22,515 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where PTCH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTCH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTCH1 survival associations across molecular data types. PTCH1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTCH1 RNA expression–survival associations across cancer types. High PTCH1 expression shows favorable associations in KIRC, UCEC, LGG, HNSC, ESCA and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PTCH1 RNA expression.
This table summarizes PTCH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PTCH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTCH1 shows lower tumor expression in KIRC, LUAD, BRCA, THCA and BLCA and higher tumor expression in CHOL. The KIRC box plot shows higher PTCH1 RNA expression in normal versus tumor tissue (log2 FC = −0.753, t-test p < 0.001).
This table shows molecular features associated with PTCH1 in patient tissues and cancer cell lines. In patient samples, PTCH1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTCH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
